Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Biologics CDMO offers end-to-end development and cGMP manufacturing for biopharma companies, focused on antibodies and biologics.
CMAB BioPharm is a contract development and manufacturing organization providing end-to-end biologic drug development and commercial manufacturing services based in Suzhou, China. The company supports biopharmaceutical clients by offering comprehensive process development, mammalian cell culture manufacturing, and drug product formulation for treatments targeting cancer, infectious diseases, and autoimmune conditions. Prior to its acquisition, the organization raised $72 million in total funding and operated advanced facilities equipped with 7,000 liters of bioreactor capacity for drug substance production. CMAB BioPharm has established strategic service partnerships with innovative drug developers such as BJ Bioscience and Laekna Therapeutics to manufacture bi-functional antibodies and other complex therapeutics. In March 2021, the company was fully acquired by industry leader WuXi Biologics and subsequently integrated into its parent organization's global manufacturing network. CMAB BioPharm was officially founded as an independent entity in 2017.
CMAB BioPharm has raised $72.0M across 2 funding rounds.
CMAB BioPharm has raised $72.0M in total across 2 funding rounds.
CMAB BioPharm has raised $72.0M across 2 funding rounds. Most recently, it raised $34.0M Series B in April 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 2, 2018 | $34M Series B | — | C Bridge Capital, Cormorant Asset Management, Tigermed | Announced |
| Jan 2, 2018 | $38M Series A | Biobay, Mengjiao Jiang | I Bridge Capital | Announced |
CMAB BioPharm has raised $72.0M in total across 2 funding rounds.
CMAB BioPharm's investors include C-Bridge Capital, Cormorant Asset Management, Tigermed, BioBAY, Mengjiao Jiang, I-Bridge Capital.